1st Quarter - Report

IGM BIOSCIENCES, INC. for IGM BIOSCIENCES, INC.

Period 1st Quarter 2023 Filed Apr 20, 2023 Signed by Andrew Womack

Official filing
Firm
IGM BIOSCIENCES, INC.
Client
IGM BIOSCIENCES, INC.
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan

LobbyistCovered position, as disclosed
ANDREW WESLEY WOMACK —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Bills named: H.R. 6833 (118th), H.R. 3932 (118th), H.R. 2617 (118th), H.R. 8236 (118th), S. 3799 (118th), S. 2076 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.